Daily CSR

Jazz Pharmaceuticals plc announced that it will share six research abstracts—including one oral presentation—at the 2026 American Academy of Neurology (AAN) Annual Meeting, scheduled for April 18–22, 2026, in Chicago.

These presentations highlight the scope of Jazz’s neuroscience work across epilepsy and sleep disorders. The data include new clinical findings on Epidiolex® (cannabidiol) in patients with conditions such as Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), tuberous sclerosis complex (TSC), and other difficult-to-treat epilepsies, as well as research on Xywav® (a mixed oxybate oral solution) in individuals with narcolepsy.

Jessa Alexander, Ph.D., who leads the neuroscience therapeutic area in global medical and scientific affairs at Jazz Pharmaceuticals, noted that the company remains committed to addressing unmet needs in rare neurological conditions. She emphasized that ongoing studies of Epidiolex and Xywav are helping deepen insights into these complex disorders, better reflect patient experiences, and guide research efforts toward improving care where gaps still exist.

Key highlights from the meeting include:

An oral presentation reporting results from a planned six-month interim analysis of the Phase 3b/4 EpiCom study. The findings showed that, after 26 weeks of Epidiolex treatment, patients with TSC-related seizures experienced reduced behavioral challenges as reported by both caregivers and clinicians. Improvements were observed across multiple assessment tools measuring neuropsychiatric symptoms and overall severity.
A poster presentation examining demographic and clinical factors linked to continued use of Epidiolex in more than 7,800 patients with LGS, DS, TSC, and other refractory epilepsies. The analysis suggests that variations in care within fragmented treatment systems may influence whether patients stay on therapy, offering insights that could help clinicians support long-term treatment adherence.
Another poster highlighting results from the DUET study, an open-label trial in adults with narcolepsy. The analysis explored outcomes such as cognitive concerns, daily functioning, work productivity, and overall disease burden in patients taking Xywav at doses above 9 grams per night. Participants who adjusted to higher doses (up to 12 grams) showed greater improvements compared to those on 9 grams, although the currently recommended adult dose remains 6–9 grams nightly.

All abstracts from the 2026 AAN Annual Meeting are available online.